黑料网

A transdermal patch is a medicated adhesive patch that is placed at the skin to deliver a specific dose of medication via the skin and into the bloodstream. Often, this promotes restoration to an injured area of the body. An advantage of a transdermal drug delivery direction over different types of medication transport such as oral, topical, intravenous, intramuscular, etc. is that the patch affords a managed release of the medication into the patient, usually via both a porous membrane covering a reservoir of drugs or via body heat melting thin layers of medication embedded in the adhesive[1]. Transdermal drug transport gives controlled release of the drug into the patient, it allows a steady blood level profile, resulting in reduced systemic side effects and, sometimes, progressed efficacy over other dosage forms [2]. The major goal of transdermal drug transport machine is to deliver drugs into systemic circulate via pores and skin at predetermined rate with minimal inter and intrapatient variations.

The transdermal drug delivery system is a technique that provides drug absorption via the skin [3]. The system has many advantages over conventional management routes such as intravenous or oral management for systemic and local drug delivery with easy administration. It is available outdoor clinical institutions, which decreases the burden on patients because of intravenous management and reduces loss from the first pass impact of the liver [4], turning in therapeutic drugs at a controlled ratio.

Transdermal delivery has numerous advantages in comparison with the oral direction. In particular, it’s far used while there is a significant first-pass effect of the liver that may prematurely metabolize drugs [5]. Transdermal delivery also has benefits over hypodermic injections, which are painful, generate risky medical waste and pose the risk of disease transmission with the aid of using needle re-use [6], in particular in growing countries. In addition, transdermal structures are non-invasive and can be self-administered. They can provide launch for long durations of time (up to one week). They also enhance patient compliance and the systems are usually inexpensive.

Transdermal delivery gives compelling opportunities to enhance vaccine administration. Although vaccines are typically macromolecules, viral particles or different large supramolecular constructs, their small (microgram) doses facilitate the possibility of transdermal transport [7]. Vaccine transport thru the skin is even extra attractive as it targets the amazing epidermal Langerhans and dermal dendritic cells that may generate a strong immune response at much lower doses than deeper injection7. The most a hit vaccine of all time— the smallpox vaccine [8], which eradicated the disorder worldwide— was administered thru the skin with the aid of a small needle device to breach the stratum cornea barrier. Although effective, this method does now no longer offer properly control over delivery, which has motivated development of latest transport methods.

Almost all transdermal patch designs, the drug is stored in a reservoir that is enclosed on one side with an impermeable backing and has an adhesive that contacts the skin on the other side63. Some designs rent drug dissolved in a liquid or gel-based reservoir, which can simplify formulations and allow the use of liquid chemical enhancers, such as ethanol [9]. These designs characteristically are composed of 4 layers: an impermeable backing membrane, a drug reservoir, a semipermeable membrane that could serve as a fee-restricting barrier and an adhesive layer. Other designs incorporate the drug into a stable polymer matrix, which simplifies manufacturing. Matrix structures can have 3 layers, by putting off the semi-permeable membrane, or simply layers, by incorporating the drug directly into the adhesive.

It is available outside medical institutions, which decreases the burden on patients caused by intravenous administration and decreases loss from the first pass effect of the liver, delivering therapeutic drugs at a controlled ratio. Overcoming the skin barrier, including the stratum corneum and epidermal layer, is necessary to develop transdermal drug formulations [10]. Although chemical and physical enhancers have been developed, they need high doses or high potency to exert efficiency, which induces irritation, causes damage, and reduces the skin barrier function. Consequently, a nanoparticle delivery system is gaining increased attention as a transdermal drug delivery carrier.

The benefits of using TDDS include the improvement of systemic bioavailability, as a result of bypassing the first pass metabolism. Variables due to oral administration, such as pH, the presence of food or enzymes and transit times can all be eliminated. TDDSs also allow for fast interruption of the treatment in the case of any adverse effects. Textile materials are often permeable, comfortable, aesthetic, breathable structures, which are also easy to use, and can usually be treated to improve their absorptive capacity.

Acknowledgement

I would like to thank my Professor for his support and encouragement.

Conflict of Interest

The authors declare that they are no conflict of interest.

1. Bariya SH, Gohel MC, Mehta TA, Sharma OP et al (2012. J Pharm Pharmacol 64:11-29.

, ,

2. Pandey PC, Shukla S, Skoog SA, Boehm RD, Narayan RJ, et al (2019) . Sensors 19:1028.

, ,

3. Wong TW (2014. J Control Release 10:193:257-69.

, ,

4. Andrews SN, Zarnitsyn V, Bondy B, Prausnitz MR, et al (2011) Int J Pharm 4:407:95-104.

, ,

5. Escobar-Chávez JJ, Bonilla-Martínez D, Villegas MA, et al (2011)  . J Clin Pharmacol 51:964-77.

,   

6. Aich K, Singh T, Dang S (2021) Drug Deliv Transl Res 25:119673.

, ,

7. Hao Y, Li W, Zhou X, Yang F, Qian Z (2017) J Biomed Nanotechnol 13:1581-1597.

, ,

8. Bilal M, Mehmood S, Raza A, Hayat U, Rasheed T (2021) . Adv Wound Care 10:204-219.

 , ,

9. Aich K, Singh T, Dang S (2021) Drug Deliv Transl Res 109:1249-1258.

, ,

10. Bariya SH, Gohel MC, Mehta TA, Sharma OP (2021) J Pharm Pharmacol 64(1):11-29.

 , ,